Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomized, dose-escalation phase 1 study

BACKGROUND: Guadecitabine (SGI-110) is a novel hypomethylating dinucleotide of decitabine (DAC) and deoxyguanosine that is resistant to degradation by cytidine deaminase. METHODS: This is a first-in-human pharmacokinetic (PK)- and pharmacodynamic (PD)-guided Phase 1 dose-escalation study in adults w...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Lancet Oncol
Main Authors: Issa, Jean-Pierre J., Roboz, Gail, Rizzieri, David, Jabbour, Elias, Stock, Wendy, O’Connell, Casey, Yee, Karen, Tibes, Raoul, Griffiths, Elizabeth A., Walsh, Katherine, Daver, Naval, Chung, Woonbok, Naim, Sue, Taverna, Pietro, Oganesian, Aram, Hao, Yong, Lowder, James N., Azab, Mohammad, Kantarjian, Hagop
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5557041/
https://ncbi.nlm.nih.gov/pubmed/26296954
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(15)00038-8
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados